Director, Preclinical Bioanalytics
Beam Therapeutics
Cambridge, Massachusetts, United States
Kelly Colletti, PhD, MBA is the Director, Preclinical Bioanalytics at Beam Therapeutics. She oversees the development and validation of bioanalytical assays supporting IND submissions for all therapeutic areas. She has over 14 years experience designing and troubleshooting ligand binding assays in bioanalysis and has more recently contributed to the validation principles for qPCR assays. Kelly has been highly engaged as an AAPS member with a passion for mentoring students and scientists. She received her PhD in cellular and molecular biology in 2005 from the University of Nevada Reno, where she also completed an MBA. Kelly lives in Reno, Nevada with her family where she enjoys recreation in the Sierra Nevada mountains.
Disclosure information not submitted.
Monday, April 24, 2023
2:30 PM – 3:15 PM ET